A device designed to treat obstructive sleep apnea helped patients breathe with fewer interruptions in a 250-patient clinical trial, according to developer Ventus Medical Inc.
The Provent Sleep Apnea Therapy from Belmont-based Ventus, which has been backed by De Novo Ventures, Mohr Davidow Ventures and Johnson & Johnson Development Corp., already has been cleared by the Food and Drug Administration and last month received its CE Mark certification from European regulators. The study, however, could provide further evidence to convince insurers to cover the device.
No comments:
Post a Comment